Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Portal hypertension is a common pathology in chronic liver disease, particularly in liver
cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The
basic reason for portal hypertension in HBV is the largely deposition of hepatic
extracellular matrixes which causes high pressure in liver vessels. One of the most common
symptoms of cirrhotic portal hypertension is gastroesophageal varices.The effective
inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic
Hepatitis and liver cirrhosis due to HBV and the anti-fibrotic strategy focusing on the
regulation of hepatic extracellular matrix may have a great benefit. Therefore, antivirals
therapy is also a basic treatment for low-grade cirrhotic portal hypertension. Fuzheng Huayu
has been found to enhance the degradation of collagens in fibrotic liver and have a good
action against liver fibrosis in patients with chronic hepatitis B. However, there are no
high quality clinical evidences which can demonstrate if the combination of anti-viral and
anti-fibrotic therapy can relieve the pressure of liver vessels and decline incidence rate
and bleeding rate of gastroesophageal varices.
Phase:
Phase 4
Details
Lead Sponsor:
ShuGuang Hospital
Collaborators:
Longhua Hospital Ruijin Hospital Shanghai Public Health Clinical Center Shanghai Zhongshan Hospital